{"id":{"repo_id":"vu-aus","oai_identifier":"oai:eprints.vu.edu.au:15580"},"canonical_url":"https://search.dev.ndltd.org/etd/vu-aus/oai:eprints.vu.edu.au:15580","repository":{"repo_id":"vu-aus","name":"Victoria University (Australia)","base_url":"https://vuir.vu.edu.au/cgi/oai2"},"display":{"title":"The development of peptide-based inhibitors of the low affinity Fc receptor, Fc [gamma] RIIa","abstract":"FcyRIIa is an activatory receptor and contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, involved in the initiation of signalling events. There is now strong evidence from transgenic mouse models and human genetic susceptibility studies that implicate FcyRIIa in a number of immune diseases including, rheumatoid arthritis, systemic lupus erythematosus (SLE) and immune thrombocytopenia purpura (ITP). FcyRHa is therefore a promising target for the development of therapeutics to treat these diseases.","abstract_html":"FcyRIIa is an activatory receptor and contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, involved in the initiation of signalling events. There is now strong evidence from transgenic mouse models and human genetic susceptibility studies that implicate FcyRIIa in a number of immune diseases including, rheumatoid arthritis, systemic lupus erythematosus (SLE) and immune thrombocytopenia purpura (ITP). FcyRHa is therefore a promising target for the development of therapeutics to treat these diseases.","abstract_has_math":false,"creators":["Cendron, Angela"],"institution":"Victoria University of Technology","degree_name":"phd","degree_level":"doctoral","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2005,"date_issued":"2005","date_published":"2005","updated_at":"2026-07-24T06:33:15Z","subjects":["1107 Immunology","School of Engineering and Science"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Cendron, Angela"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2005"]},{"key":"dc:date.issued","label":"Date","values":["2005"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["School of Molecular Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["Victoria University of Technology"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://vuir.vu.edu.au/15580/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["doctoral"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["phd"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["1107 Immunology","School of Engineering and Science"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://vuir.vu.edu.au/15580/3/CENDRON%20Angela-theses_nosignature.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["FcyRIIa is an activatory receptor and contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, involved in the initiation of signalling events. There is now strong evidence from transgenic mouse models and human genetic susceptibility studies that implicate FcyRIIa in a number of immune diseases including, rheumatoid arthritis, systemic lupus erythematosus (SLE) and immune thrombocytopenia purpura (ITP). FcyRHa is therefore a promising target for the development of therapeutics to treat these diseases."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dc:title","label":"Title","values":["The development of peptide-based inhibitors of the low affinity Fc receptor, Fc [gamma] RIIa"]}]}],"canonical_facts":{"dc:creator":["Cendron, Angela"],"dc:date":["2005"],"dc:date.issued":["2005"],"dc:description.abstract":["FcyRIIa is an activatory receptor and contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, involved in the initiation of signalling events. There is now strong evidence from transgenic mouse models and human genetic susceptibility studies that implicate FcyRIIa in a number of immune diseases including, rheumatoid arthritis, systemic lupus erythematosus (SLE) and immune thrombocytopenia purpura (ITP). FcyRHa is therefore a promising target for the development of therapeutics to treat these diseases."],"dc:format":["text"],"dc:identifier.uri":["https://vuir.vu.edu.au/15580/3/CENDRON%20Angela-theses_nosignature.pdf"],"dc:language":["en"],"dc:publisher.department":["School of Molecular Sciences"],"dc:publisher.institution":["Victoria University of Technology"],"dc:relation.isreferencedby":["https://vuir.vu.edu.au/15580/"],"dc:subject":["1107 Immunology","School of Engineering and Science"],"dc:title":["The development of peptide-based inhibitors of the low affinity Fc receptor, Fc [gamma] RIIa"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["doctoral"],"dc:type.qualificationname":["phd"]},"updated_at":"2026-07-24T06:33:15Z"}